Jothydev Kesavadev
MD, FRCP(London), FACE, FRCP(Glasgow),
FACP, FRSSDI

Jothydev’s Diabetes & Research Center
JDC Junction, Mudavanmugal,
Trivandrum, Kerala, India 695032
tel +91 471 2356200
fax +91 471 2356666
cell +91 984 6040055
www.jothydev.net, jothydev@gmail.com

Research Diabetologist based in Kerala, South India.

    • Several National and International original presentations and publications to his credit
    • Strong advocate of diabetes education for public since 1995 through electronic, visual and print media including new papers, magazines, radio, television and YouTube
    • More than 3000 TV programs, 3000 articles and 200 you tube videos on diabetes education
    • Lectured at Scientific forums for physicians in more than 25 countries
    • First speaker from Kerala at the American Diabetes Association(ADA)
    • First invited speaker at International Diabetes Federation(IDF) and Advanced Technologies & Treatments for Diabetes(ATTD),Europe from Kerala
    • 10 years of experience as a medical teacher both for undergraduates and post graduates
    • Much sought after National faculty
    • Introduced the revolutionary telemedicine concept of patient follow up via Diabetes Tele Management System(DTMS®) in 1997.
    • Introduced in 1997,the multi-disciplinary professional diabetes team approach for successful management of diabetes,
    • Internationally known expert in the field of Insulin pumps, Continuous Glucose Monitoring and Telemedicine
    • Editor of ‘Diabetes Gems’ a free internet based monthly scientific newsletter with more than 125,000 readers for more than 8 years (http://www.jothydev.com/newsletter/)
    • Organizer of >650 Mega Diabscreen Kerala free diabetes awareness, detection and treatment medical camps across Kerala ( a project of P.Kesavadev Trust)
    • Organizer of various National and International Scientific Conferences
    • Reviewer of more than a dozen scientific journals including Diabetes Care, Diabetes Technology & Therapeutics, Diabetes Science & Technology and Indian Journal of Endocrinology & Metabolism etc.,
    • Course director for various diabetes training programs for doctors: RSSDI, UK, JDC etc.,
    • Principal Investigator of various Multinational Clinical Trials
    • Authored chapters in various text books

Present Positions:

  • CEO and Director: Jothydev's Diabetes Research Center, Trivandrum
  • CEO & Chairman: Jothydev’s Diabetes Research Center, Cochin
  • Chairman: Kesavadev Trust Type 1 Diabetes Project, “KT1DP Sweet Stars”
  • Chairman and Managing Trustee: Diabscreen Kerala, P. Kesavadev Trust
  • Managing Director: Living Longer Life Care (Private Limited)

Previously:

  • Asst.Professor of Medicine: Government Medical College, Trivandrum- 2001-2002
  • Lecturer in Internal Medicine: Government Medical College, Trivandrum- 1994-2001

Education:

  • MBBS, Medical College, Trivandrum, Kerala, India: Dec 1989 (Undergraduate Course)
  • MD, Medical College, Trivandrum, Kerala, India: Oct 1996 (Post Graduate in Internal Medicine)
  • Endocrinology Research Fellow at Mayo Clinic, MN, USA: 2002- 2003
  • Fellow of the Royal College of Physicians(FRCP), Glasgow: 2014
  • Fellow of the American College of Physicians(FACP): 2015
  • Fellow of the Royal College of Physicians(FRCP), London:2016
  • Fellow of the Research Society for the Study of Diabetes in India: 2016
  • Fellow of the Research Society for the Study of Diabetes in India(FRSSDI), India: 2017
  • Fellow of the American College of Endocrinology(FACE), USA: 2017

Teaching Experience:

  • Served as Asst.Professor of Medicine: Government Medical College, Trivandrum: 2001-2002
  • Served as Lecturer in Internal Medicine: Government Medical College, Trivandrum: 1994-2001
  • Teaching Faculty for the RSSDI Fellowship Course in Diabetology: 2014-present
  • Faculty for the Fellowship course in diabetes at Jothydev’s Diabetes Research Centre: 2014-present
  • Faculty for the MSc.Cert. course in Endocrinology/ Diabetes courses, South Wales University, UK: 2016 October(continuing)

Major areas of Research:

  • Diabetes Education, CGM, Insulin Pumps, Telemedicine

Memberships in Professional Associations:

  • American Association of Clinical Endocrinologists (AACE)
  • American Diabetes Association(ADA)
  • American Geriatrics Society (AGS)
  • European Association for the Study of Diabetes (EASD)
  • Research Society for the Study of Diabetes in India(RSSDI)
  • Association of Physicians India (API)
  • Indian Medical Association(IMA)
  • Geriatric Society of India
  • Indian Medical Association(AMS)
  • Diabscreen Kerala, doctor’s forum

Honors

  • 2007 Young achiever for 2007 by Humanity in Unity USA
  • 2008 Rajiv Gandhi Shiromani Award
  • 2011 International Kohinoor Award
  • 2013 Award by Geriatric Society of India
  • 2013 Incredible Medical Expert of the Decade Award
  • 2014 Mahatma Gandhi Cultural Award
  • 2014 Most Promising Healthcare Centre in diabetes education and treatment Award
  • 2015 Sahridayavedi Award
  • 2015 Jeevan Raksha Award by Anti Narcotic Action Centre of India

Select Original Research Publications:

  1. Our First 825 T2DM Patients on 14-Day Factory-Calibrated Glucose Monitoring System: Clinical Utility and Challenges. Kesavadev J, Shankar A, Ashok AD, Srinivas S, Ajai NA, Sanal G, Krishnan G, Ramachandran L, Jothydev S. Journal of Diabetes Science and Technology. 0(0):1932296817717504.
  2. Assessing the Therapeutic Utility of Professional Continuous Glucose Monitoring in Type 2 Diabetes Across Various Therapies: A Retrospective Evaluation. Kesavadev J, Vigersky R, Shin J, Pillai PBS, Shankar A, Sanal G, Krishnan G, Jothydev S. Adv Ther. 2017.
  3. Efficacy and safety concerns regarding Complementary and Alternative Medicine use among diabetes patients. Kesavadev J. The Journal of the Pakistan Medical Association. 2017;67(2):316.
  4. Consensus recommendations on exploring effective solutions for the rising cost of diabetes. Sadikot SM, Das AK, Wilding J, Siyan A, Zargar AH, Saboo B, Aravind SR, Sosale B, Kalra S, Vijayakumar G, Manojan KK, Maheshwari A, Panda JK, Banerjee S, Chawla R, Vasudevan SP, Sundar OSS, Kesavadev J. Diabetes & Metabolic Syndrome: Clinical Research & Reviews. 2017.
  5. Platelet Proteins from Diabetic Subjects Cause Phenotypic Changes in Endothelial Cells In-Vitro. Hilary S, Shahna S, Kesavadev J, Bhatt A. International Journal of Life Science And Pharma Research. 2017;7(1):61-71.
  6. Unproven Therapies for Diabetes and Their Implications. Kesavadev J, Saboo B, Sadikot S, Das AK, Joshi S, Chawla R, Thacker H, Shankar A, Ramachandran L, Kalra S. Adv Ther. 2016:1-18.
  7. Unproven therapies for diabetes and its implications. Kesavadev J, Saboo B, Sadikot S, Das A K, Joshi S, Chawla R, Thacker H, Shankar A, Ramachandran L, Kalra S. Advances in Therapy. (Accepted for publication).
  8. Insulin pump therapy in pregnancy. Kesavadev J. J Pak Med Assoc. 2016 Sep;66(9 Suppl 1): S39-44.
  9. Use of Retrospective Continuous Glucose Monitoring for Optimizing Management of Type 2 Diabetes in India. Mohan V, Jain S, Kesavadev J, Chawla M, Mutha A, Viswanathan V, Saboo B, Kovil R, Mithal A, Punatar D, Shin J. J Assoc Physicians India. 2016 Apr;64(4):16-21.
  10. The two levels of care for diabetes in a developing country: Mechanisms for improved intermediate health outcomes. Vitale RJ, Pillai PB, Krishnan G, Jothydev S, Kesavadev J. Diabetes Metab Syndr. 2016 Jan-Mar;10(1 Suppl 1): S90-4.
  11. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. LEADER Trial Investigators. N Engl J Med. 2016 Jul 28;375(4):311-22.
  12. Consensus Statement on Management of Post-Prandial Hyperglycemia in Clinical Practice in India. Aravind S, Saboo B, Sadikot S, Shah SN, Makkar B, Kalra S, Kannampilly J, Kesavadev J, Ghoshal S, Zargar A, Nigam A, Hazra D, Tripathi K, Dharmalingam M, Shah P, Gandhi P, Sahay R, Unnikrishnan R, Gupta S, Bajaj S, Mukhopadhyay S, Kale S. J Assoc Physicians India. 2015 Aug;63(8):45-58.
  13. Telemedicine for diabetes care: An Indian perspective - feasibility and efficacy. Kesavadev J, Saboo B, Shankar A, Krishnan G, Jothydev S. Indian J Endocrinol Metab. 2015 Nov-Dec;19(6):764-9.
  14. CSII as an Alternative Therapeutic Strategy for Managing Type 2 diabetes: Adding the Indian Experience to a Global Perspective. Kesavadev J, Shankar A, Pillai PB, Saboo B, Joshi S, Krishnan G, Jothydev S. Curr Diabetes Rev. 2015 Dec 7.
  15. Intensifying Insulin Therapy in Type 2 Diabetes: Choices & Challenges. Kumar A, Kesavadev J, Sethi B, Jain SM, Guruprasad CS, Shah SN. J Assoc Physicians India. 2015 May;63(5 Suppl):8-14.
  16. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. TECOS Study Group. N Engl J Med. 2015 Jul 16;373(3):232-42.
  17. Fasting in Ramadan with an insulin pump. Kesavadev J. J Pak Med Assoc. 2015 May;65(5 Suppl 1):S47-50.
  18. Consensus evidence-based guidelines for use of insulin pump therapy in the management of diabetes as per Indian clinical practice. Kesavadev J, Jain SM, Muruganathan A, Das AK; Diabetes Consensus Group. J Assoc Physicians India. 2014 Jul;62(7 Suppl):34-41.
  19. Efficacy and safety of liraglutide therapy in 195 Indian patients with type 2 diabetes in real world setting. Kesavadev J, Shankar A, Gopalakrishnan G, Jothydev S. Diabetes Metab Syndr. 2015 Jan-Mar;9(1):30-3.
  20. Understanding the safety of the new ultra long acting basal insulin. Ramachandran A, Gupta V, Kesavadev J, Kalra S. J Assoc Physicians India. 2014 Jan;62(1 Suppl):35-42.
  21. Challenges in Type 1 diabetes management in South East Asia: Descriptive situational assessment. Kesavadev J, Sadikot SM, Saboo B, Shrestha D, Jawad F, Azad K, Wijesuriya MA, Latt TS, Kalra S. Indian J Endocrinol Metab. 2014 Sep;18(5):600-7.
  22. Consensus guidelines for glycemic monitoring in type 1/type 2 & GDM. Kesavadev J, Sadikot S, Wangnoo S, Kannampilly J, Saboo B, Aravind SR, Kalra S, Makkar BM, Maji D, Saikia M, Anjana RM, Rajput R, Singh SK, Shah S, Dhruv U, Vishwanathan V. Diabetes Metab Syndr. 2014 Jul-Sep;8(3):187-95.
  23. Improvement of glycemic control with addition of insulin detemir to existing antidiabetic therapy: a sub-group analysis of A1chieve observational study. Kesavadev J, Joshi SR. J Assoc Physicians India. 2013 Jan;61(1 Suppl):28-30.
  24. Clinical experience with insulin detemir, biphasic insulin aspart and insulin aspart in people with type 2 diabetes: Results from the Trivandrum cohort of the A1chieve study. Kesavadev J. Indian J Endocrinol Metab. 2013 Nov;17(Suppl 2):S565-8.
  25. Barriers and solutions to diabetes management: An Indian perspective. Wangnoo SK, Maji D, Das AK, Rao PV, Moses A, Sethi B, Unnikrishnan AG, Kalra S, Balaji V, Bantwal G, Kesavadev J, Jain SM, Dharmalingam M. Indian J Endocrinol Metab. 2013 Jul;17(4):594-601.
  26. Once-daily initiation of basal insulin as add-on to metformin: a 26-week, randomized, treat-to-target trial comparing insulin detemir with insulin glargine in patients with type 2 diabetes. Meneghini L, Kesavadev J, Demissie M, Nazeri A, Hollander P. Diabetes Obes Metab. 2013 Aug;15(8):729-36.
  27. Cost-effective use of telemedicine and self-monitoring of blood glucose via Diabetes Tele Management System (DTMS) to achieve target glycosylated hemoglobin values without serious symptomatic hypoglycemia in 1,000 subjects with type 2 diabetes mellitus--a retrospective study. Kesavadev J, Shankar A, Pillai PB, Krishnan G, Jothydev S. Diabetes Technol Ther. 2012 Sep;14(9):772-6.
  28. Suggested use of vaccines in diabetes. Kesavadev J, Misra A, Das AK, Saboo B, Basu D, Thomas N, Joshi SR, Unnikrishnan AG, Shankar A, Krishnan G, Unnikrishnan R, Mohan V. Indian J Endocrinol Metab. 2012 Nov;16(6):886-93.
  29. Liraglutide therapy beyond glycemic control: an observational study in Indian patients with type 2 diabetes in real world setting. Kesavadev J, Shankar A, Krishnan G, Jothydev S. Int J Gen Med. 2012;5:317-22.
  30. Continuous insulin infusion systems in type 2 diabetes. Kesavadev J. J Assoc Physicians India. 2011 Apr;59 Suppl:41-3.
  31. An Asian Indian woman with Wolfram syndrome on insulin pump: successful pregnancy and beyond. Kesavadev J, Kumar A, Shankar A, Gopalakrishnan G, Permutt MA, Wasson J, Jothydev S. Diabetes Technol Ther. 2011 Jul;13(7):781-5.
  32. Use of insulin pumps in India: suggested guidelines based on experience and cultural differences. Kesavadev J, Das AK, Unnikrishnan R 1st, Joshi SR, Ramachandran A, Shamsudeen J, Krishnan G, Jothydev S, Mohan V. Diabetes Technol Ther. 2010 Oct;12(10):823-31.
  33. Reduction of glycosylated hemoglobin following 6 months of continuous subcutaneous insulin infusion in an Indian population with type 2 diabetes. Kesavadev J, Balakrishnan S, Ahammed S, Jothydev S. Diabetes Technol Ther. 2009 Aug;11(8):517-21.
  34. Gatifloxacin induced abnormalities in glucose homeostasis in a patient on glimepiride. Kesavadev J, Rasheed SA. J Assoc Physicians India. 2006 Dec;54:951-2.
  35. Diabetes in old age: an emerging epidemic. Kesavadev JD, Short KR, Nair KS. J Assoc Physicians India. 2003 Nov;51:1083-94.

Selected Chapters in textbooks:

  • Kesavadev J. Brittle Diabetes: Challenges to the Physicians. Chapter 30, Section 12. SMART Medicine update -2017. Jaypee Brothers Medical Publishers 2017.
  • Kesavadev J. Insulin Pump Therapy: How to Choose the Right Candidate. Chapter 8. RSSDI Diabetes Update 2016.
  • Kesavadev J. In Hospital Management of Diabetes mellitus. API Progress in Medicine 2017
  • Kesavadev J. Evolution of Path-breaking Technologies in Diabetes. Chapter 21. Volume 2. API Progress in Medicine 2016
  • Kesavadev J. The Bittersweet Aroma of Inhaled Insulin. Chapter 18. RSSDI Annual Conference Update 2015
  • Kesavadev J. Use of Insulin Pump in Type 1 Diabetes Mellitus. Chapter 18. Clinical Case Series in Diabetes. Jaypee Brothers Medical Publishers 2015.
  • Kesavadev J. Will the Technological Advances in Devices have Place in Diabetes Management in India? Micro labs Ltd. 2015
  • Kesavadev J. Clinical Benefits of Liraglutide: Taking Therapy into the Real World. API Medicine Update Vol. 24: 2014
  • Kesavadev J. Insulin pumps in Type 1 diabetes. RSSDI Annual Conference Update 2014
  • Kesavadev J. Immunization in Diabetes. Diabetes Suraksha. Macmillan Medical Publishers 2014
  • Kesavadev J. Continuous Glucose Monitoring System, Chapter 41, RSSDI Textbook of Diabetes 2013.
  • Kesavadev J. Various Emerging Techniques in Insulin Delivery Systems. Innovative Approaches in Type 2 diabetes. Chapter 42. Page 398-408. Micro labs Ltd.
  • Kesavadev J. Very Low Protein Diet with Ketoanalogue Supplementation in Diabetic Keidney Disease: Case Studies. Dietary Protein Restriction in Chronic Kidney Disease. Page 35-44 Published by Elsevier India Pvt.Ld.
  • Kesavadev J. Insulin Pump in Type 2 diabetes mellitus. Jaypee Brothers Medical Publishers (P) Ltd.Page 120-133 World Clinics Diabetology Type 2 diabetes mellitus.World Clin Diabetol.2014;1(1):120-33
  • Kesavadev J. Insulins in Continuous Subcutaneous Insulin Infusion”, Asian Journal of Diabetology, April-June 2010
  • Kesavadev J. Newer Insulin and Insulin pumps", The Journal of the Association of Physicians of India (Tamil Nadu Chapter) (TAPIJ), May-Aug 2010

Select Presentations:

  • American Diabetes Association, 77th Scientific Sessions, San Diego, California, 2017
      Halting CKD Progression in Diabetes with Virtual Interactions- a 5 year Retrospective Analysis.
  • American Diabetes Association, 77th Scientific Sessions, San Diego, California, 2017
      The significance of repeated education in correcting insulin injection techniques and improving glycemic control.
  • Diabetes India 2017- Invited talk
      The limitation of HbA1c - Flash Glucose Monitoring: Clinical Use.
  • Diabetes India 2017- Invited talk
      Bionic Pancreas: The Dream Come True?
  • American Diabetes Association, New Orleans, 2016
      How Successful Is Lifestyle Advice in Preventing the Progression of Prediabetes to Diabetes. Comparison of the New Factory Calibrated Sensor with Existing CGM Sensor.
  • Advanced Technologies & Treatments for Diabetes 9th International Conference 2016
      Periodic follow up with telemanagement system for 15 years and significant reduction in vascular complications in T2DM. Abstracts from ATTD 2016 9th International Conference on Advanced Technologies & Treatments for Diabetes. Milan, Italy–February 3–6, 2016. Diabetes Technology & Therapeutics. February 2016, 18(S1): A-1-A-139.
      Comparing iPro2 with Libre for Sensor Accuracy and User Friendliness. Abstracts from ATTD 2016 9th International Conference on Advanced Technologies & Treatments for Diabetes. Milan, Italy–February 3–6, 2016. Diabetes Technology & Therapeutics. February 2016, 18(S1): A-1-A-139.

  • International Diabetes Federation World Diabetes Congress 2015
      ’How significant are wrong injection techniques in a real world diabetes care setting?’. World Diabetes Congress, IDF, Vancouver, Canada: 30 Nov-4 Dec 2015
      ‘Cost effective customisation of targets: Outcomes after 12 years of telemedicine in 853 patients with type 2 diabetes’. World Diabetes Congress, IDF, Vancouver, Canada: 30 Nov-4 Dec 2015
      ‘How proactive is the spouse support in diabetes care?. World Diabetes Congress, IDF, Vancouver, Canada: 30 Nov-4 Dec 2015
      Unity in diversity: Religious festivals and its impact on diabetes in India’. World Diabetes Congress, IDF, Vancouver, Canada: 30 Nov-4 Dec 2015
  • American Diabetes Association, Boston, 2015
      Comparing two models of diabetes care: comprehensive education and telemonitoring vs. limited care. 743-P
      Insulin-sparing effect of and Severe Hypoglycemia with Sitagliptin vs. Glimepiride. 2379-PO
      Periodic CGM in T2DM: exploring benefits across various therapy choices.964-P
      Exploring and resolving the impact of food on post prandial glycemic excursions in a rice-eating population in S.India. 2486-PO
      Utilization of Biosimilar insulin in Asian patients with diabetes – The Joint Asia Diabetes Evaluation (JADE) program.1023-P
  • Advanced Technologies & Treatments for Diabetes 8th International Conference 2015
      Impact of Insulin Pump Therapy on Erectile Dysfunction in Type 2 Diabetes
      Role of Home Blood Pressure Monitoring in Halting the Progression of Diabetic Kidney Disease: 6 Year Follow up Data
  • European Association for the Study of Diabetes (EASD), 2014
      Prevalence of undetected thyroid disorders in subjects with diabetes in South India: a cohort analysis
  • American Diabetes Association, San Francisco, US 2014
      Continuous Glucose Monitoring in 432 T2D Patients for Assessment of Safety and Cost effectiveness in Reaching A1C Targets.
  • Advanced Technologies & Treatments for Diabetes 7th International Conference 2014,Invited Speaker: ‘Use of Insulin Pumps in T2D in India:
    merits and demerits learnt over a decade.’
      Clinical Utility of CGM in pre-diabetes and its impact on modifying lifestyles.
      Live Brief Weekly Educational Questionnaire Via DTMS® as a tool to improve the acceptability and outcome in Type 2 Diabetes.
  • International Diabetes Federation World Diabetes Congress 2013
      The young Indian female with type 1 diabetes: challenges with marriage- Oral presentation Continuous customised education via telemedicine: outcome data of events over 8 years
      Safety of pneumococcal and influenza vaccine in diabetes patients in South India
      High prevalence of Hypertension in Kerala population: Diabscreen Kerala 22
  • European Association for the Study of Diabetes (EASD), 2013.
      C-peptide levels not affected by duration of diabetes in a telemedicine based long-term follow up programme
  • European Association for the Study of Diabetes (EASD), 2012.
      Low requirements for average statins dosage in South Indian populations titrated to target lipid parameters.
  • Advanced Technologies and Treatment for Diabetes (ATTD), Paris, France, 2013
      Attitudes and Behaviour Of Type 2 Diabetes Patients on Insulin Pumps.
      Diabetes Technology & Therapeutics. February 2013
      Glycemic Variability in Type 2 Diabetes Correlates with Total Daily Dose of Insulin And Use of Sulfonlyureas. Diabetes Technology & Therapeutics. February 2013
  • Advanced Technologies and Treatment for Diabetes (ATTD), Barcelona, Spain, 2012
      Acceptance of Continuous Glucose Monitoring (CGM) as a routine investigation in Diabetes
      Geographical Location And Effectiveness Of A Simple Telemedicine Program (DTMS®) In Diabetes
  • American Diabetes Association, Chicago, Illinois 2013
      Time of Insulin Initiation, Duration of disease and onset of Erectile Dysfunction in Indian men with T2D.
      Long Term Impact of Initial Insulin Therapy in New Onset T2D: 5 year Retrospective Data.
      Superiority of a Telemedicine Based Counselling in Ensuring Multi Drug Compliance in T2D.
      Normal Vitamin D Levels Correlates with Lower HbA1c: A Cross Sectional Study Among 1270 Type 2 Diabetes Patients in South India.
  • American Diabetes Association, Philadelphia, Pennsylvania 2012
      High Bed Time Glucose and Early Morning Low Sugars in Elderly Subjects with Type 2 Diabetes(T2DM): An Incidental Finding with Clinical Significance 881-P.
      Patterns of Glycemic variability(GV) in Indian Type 2 diabetes(T2DM) patients on Insulin and Oral Hypoglycemic Agents(OHAs) and its Correlation with A1c and Hypoglycemia 2343-PO.
      Efficacy and Safety of Liraglutide in 195 Patients with Type 2 Diabetes in India: A Retrospective Analysis 2403-PO
  • International Diabetes Federation, World Diabetes Congress, Dubai 2011
      Tele-medicine via DTMS® is cost-effective and satisfactory: still why it fails in minority with T2DM?- O-0427
      Acceptability of a home delivered assessment of lab & vital signs in Diabetes mellitus & its role in treatment motivation P-1798
      Effectiveness of Liraglutide in Routine Clinical Practice: Six Months Follow-Up Data from India P-1852
  • American Diabetes Association, San Diego, California, 2011
      A1c, BP and LDL goals: Successful Use of Telemedicine (DTMS) in 1000 Compliant T2DM Subjects over 6 Months: 229-OR
      Utility of CGM over Conventional SMBG in Making Treatment Changes in Insulin Requiring T2DM Patients: 912-P
      Significance of Screening for Thyroid Disorders in Type 2 Diabetes : 1377-P
      Change in Antihypertensive Medication Dose Following Initiation of Liraglutide in Patients with Type 2 Diabetes Mellitus: 2357-PO
  • Advanced Technologies and Treatment for Diabetes (ATTD), London, UK, 2011
      CGM as a tool For Therapeutic Decision Making (TDM) In Type 2 Diabetes Mellitus P-108
      Pregnancy, Wolfram Syndrome and Insulin Pump: benefits beyond glycemic controlP-109
  • ESICON, 2010
      `Effectiveness and Tolerability of Once Daily Human GLP-1 Analogue Liraglutide in Patients with Type 2 Diabetes in A Real Life Clinical Practice Setting-PO
  • American Diabetes Association, Orlando, USA, 2010
      Telefollow up and SMBG Via “DTMS”- A Cost Effective Tool for A1c Lowering – 2083-PO
      High Prevalence of Elevated Transaminases among T2DM in S.India – 2340-PO
  • American Diabetes Association, New Orleans, USA, June 2009 (speaker)
      Requirement of high dosage of insulin in previous users of Glibenclamide with uncontrolled diabetes – 2079-PO.
      Role of CGM in modifying Diet and Lifestyles in Diabetes subjects – 268-OR.
  • American Diabetes Association, San Francisco, USA, June 2008
      Experiences with Insulin Pump in 52 Patients with Type 2 Diabetes in India- 2021-PO
      Insulin Aspart Induced Lipoatrophy in a Patient on Insulin Pump- 2093- PO
      High Prevalence of Dyslipidemia and Hypertension Detected in a Screening Program for Diabetes in a Rural population of a Southern State in India, Kerala (DIABSCREEN KERALA-04) – 2424-PO
      A Study on the Effects of Acarbose in Reducing Post-Prandial Blood Glucose and Achieving HbA1c – 438-P
  • American Diabetes Association, Chicago, June 2007
      Achieving Desirable Glycemic Targets without the risks of Hypoglycemia using a Tele titration program -0421-P
      Dramatic Response of Painful Peripheral Neuropathy with Insulin Pump in Type 2 Diabetes -2097-PO
  • World Diabetes Congress, International Diabetes Federation, Montreal, Canada 2009
      Good Nutrition: Avoidance of excess weight with Pumps- Symposium, (an invited Speaker)
      Low compliance of Statins in Kerala Rural Population (Diabscreen 14)
      Successful outcome of a multidisciplinary team over an individual approach in imparting diabetes education.
  • Advanced Technologies and Treatment for Diabetes, Basel, Switzerland, 2010
      “Significant Alleviation of Neuropathic Pain with Insulin Pumps (CSII) in T2DM subjects previously on MDI”, Abstract [57]
  • Advanced Technologies and Treatment for Diabetes, Greece, 2009
      Reasons for non compliance to Diabetes Tele Medicine Based Follow up Program in Type 2 Diabetes.
      Insulin Pump in 56 Type 2 diabetes subjects: Improvement of sexual satisfaction and neuropathic symptoms.
  • Research Activities:

    As Principal Investigator for several research studies, a few are given below –

    • Principal Investigator for Inhaled human insulin with the AERx iDMS as prandial monotherapy compared to combination therapy with metformin and glimeperide in type 2 diabetes: an 18 week, open-label, multicentre, randomized, parallel group trial with an 8 week extension to investigate efficacy and safety. (Protocol ID: NN1998-1787)

    • A 26 weeks randomized, multinational, open-labelled, two armed, parallel group, treat-to-target, once daily treatment trial with insulin detemir versus insulin glargine both in combination with metformin in subjects with type 2 diabetes.(NN304-1768)

    • Trial to Evaluate Cardiovascular Outcomes after Treatment with Sitagliptin in Patients with type 2 Diabetes Mellitus and Inadequate Glycemic Control on Mono- or Dual Combination Oral Antihyperglycemic Therapy (TECOS)

    • A trial investigating the efficacy and safety of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen (NN1250-3585)(DEGLUDEC STUDY)

    • An extension trial to NN1250-3585 investigating safety and efficacy of NN1250 compared to insulin detemir in subjects with type 1 diabetes mellitus in a basal/bolus treatment regimen. NN1250-3725

    • Use of telemedicine based self monitoring of blood glucose program to achieve target HbA1c value without serious symptomatic hypoglycaemia along with economic benefit in 1000 patients with type 2 diabetes mellitus. : Retrospective study (IIS)

    • A 24 week, open, multicentre, comparative study of 2 strategies (including insulin glargine versus premixed insulin) for the therapeutic management of patients with type 2 diabetes failing oral agents.LANTU_C_04589

    • A 24 –week, multi-center, double blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of vildagliptin 50 mg bid as an add-on therapy to insulin, with or without metformin, in patients with type 2 diabetes mellitus CLAF237A23135

    • A long-term, multi-centre, international, randomized, double-blind, placebo-controlled trial to determine Liraglutide effects on cardiovascular events (LEADER : EX2211-3748)

    • A 20 week randomized ,multinational, open labeled, 2-armed,parallel group comparison of twice daily subject driven titration of biphasic insulin aspart (BIAsp) 30 versus twice daily investigator-driven titration of biphasic insulin aspart (BIAsp) 30 both in combination with Metformin in subjects with type 2 diabetes inadequately controlled on basal insulin analogues

    • Effects of Continuous Subcutaneous Insulin Infusion (CSII) on Erectile Dysfunction in T2DM Patients: A Prospective, Exploratory, Controlled Trial. (IIS)

    • An open labelled, randomized, active-controlled, parallel-arm, single-center study on effect of sitagliptin on T2DM patients on treatment with metformin and insulin.(IIS)

    • The Indian Prevention of Diabetes Study – RSSDI

    • Evaluation of the efficacy and tolerability of bromocriptine in the treatment of uncontrolled type 2 diabetes mellitus (USV/BROMO/001)

    • PERSISTence on glimepiride-metformin fixed combination in everyday practice in Asia type 2 diabetes patients

    Academic Activities:

      • Accredited Centre for RSSDI Fellowship Course in Diabetology
      • Runs JDC Fellowship Course in Diabetes
      • Runs Foundation Course and MSc Cert. in Diabetes and Endocrinology, UK